BioCryst_PrimaryLogo_R_2C_RGB.jpg
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
November 22, 2021 07:00 ET | BioCryst Pharmaceuticals, Inc.
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
Intellia.jpg
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET | Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
BioCryst.jpg
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
May 06, 2020 07:00 ET | BioCryst Pharmaceuticals, Inc.
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
BioCryst.jpg
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
November 20, 2018 07:00 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
BioCryst.jpg
BioCryst Reports Third Quarter 2018 Financial Results
November 06, 2018 07:00 ET | BioCryst Pharmaceuticals, Inc.
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...
BioCryst.jpg
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
November 05, 2018 07:00 ET | BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual...
logo.jpg
Shire plc: CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks
October 19, 2018 08:00 ET | Shire plc
CHMP Recommends EU Marketing Authorisation of lanadelumab for the Prevention of HAE Attacks -       If approved, lanadelumab would be the first monoclonal antibody for the preventive treatment of...
Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
August 27, 2018 17:14 ET | TAKHZYRO
FOR US MEDIA ONLY  -  In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an 87% reduction in mean monthly attacks vs. placebo (0.26 vs. 1.97, n=27 vs. n=41) -  All secondary...
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
July 27, 2017 16:01 ET | KalVista Pharmaceuticals, Inc.
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE,...
KalVista Pharmaceuticals to Recognize HAE Day 2017
May 15, 2017 07:30 ET | KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, May 15, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...